文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-氟昔洛韦(18F-Fluciclovine)检测前列腺癌骨转移的诊断效能

Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
PubMed 文献 · Clin Nucl Med · 2018-01-01

本文综述18F-氟昔洛韦PET/CT检测前列腺癌骨转移的临床前与临床资料。部分回顾性和2项前瞻性研究提示,其可检出既往骨特异性影像阴性、生化复发(BCR)患者早期骨髓受累;作者认为其似可为BCR患者骨转移早期检出提供有用信息,尚需与其他标准及新型影像方法比较。

要点

  • 18F-氟昔洛韦是已获欧洲和美国批准的合成氨基酸类PET示踪剂,用于前列腺癌根治性治疗后生化复发(BCR)男性。
  • 累积临床前数据及部分回顾性和2项前瞻性临床研究提示,18F-氟昔洛韦可检出既往骨特异性影像阴性BCR患者的早期骨髓受累。
  • 作者认为18F-氟昔洛韦PET/CT似可为BCR前列腺癌男性骨转移早期检出提供有用信息。

核心结论

  • 18F-氟昔洛韦PET/CT似可为前列腺癌生化复发(BCR)男性骨转移的早期检出提供有用信息。
  • 尚需进一步研究,将18F-氟昔洛韦PET/CT与其他标准和新型影像方法在初始分期、BCR和去势抵抗阶段的诊断效能进行比较。

研究设计与样本

  • 综述:对18F-氟昔洛韦PET/CT诊断效能的现有临床前与临床资料进行综合回顾。
  • 所汇总的临床证据包括部分回顾性研究和2项前瞻性临床研究。

主要发现

  • 累积临床前数据及部分回顾性和2项前瞻性临床研究结果提示,18F-氟昔洛韦可检出既往骨特异性影像阴性BCR患者的早期骨髓受累。
  • 骨是前列腺癌患者最常见的转移部位。

临床怎么用

  • 作者认为,18F-氟昔洛韦PET/CT似可为前列腺癌BCR男性骨转移的早期检出提供有用信息。

局限性

  • 作者指出,尚需进一步研究,将18F-氟昔洛韦PET/CT与其他标准和新型影像方法在初始分期、BCR和去势抵抗阶段的诊断效能进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: F-fluciclovine is a synthetic amino acid radiotracer that has recently been approved in Europe and the United States for PET imaging in men with biochemical recurrence (BCR) of prostate cancer after prior definitive treatment. Accurate identification of the sites of disease in patients presenting with BCR of prostate cancer is important in determining the appropriate treatment. Bone is the most frequent site of metastatic disease in patients with prostate cancer. METHODS: We conducted a comprehensive review of the available preclinical and clinical data on the diagnostic performance of F-fluciclovine PET/CT in an attempt to draw practical and general conclusions on the utility and limitations of F-fluciclovine PET/CT in localization of osseous metastatic disease in prostate cancer. RESULTS: The cumulative preclinical data and results of some retrospective and 2 prospective clinical studies suggest that F-fluciclovine can detect early bone marrow involvement in patients with BCR of prostate cancer and negative prior bone-specific imaging findings. CONCLUSIONS: F-fluciclovine PET/CT seems to offer useful information for early detection of bone metastases in men with BCR of prostate cancer. Additional investigations will be needed to compare the diagnostic performance of F-fluciclovine PET/CT to other standard and novel imaging methods in initial staging, BCR, and castrate-resistant phases of disease.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chau A, Gardiner P, Colletti PM, et al. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clin Nucl Med. 2018. PMID: 29762238. doi:10.1097/RLU.0000000000002130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。